Aviceda Therapeutics has announce the appointment of Chris Adams, PhD, MBA, and Nancy K. Thomason, MBA, to their board of directors, effective immediately. Aviceda is a preclinical stage biotech company focused on the next generation of glyco-immune therapeutics utilizing the Glyco-Code technology to address the innate immune system and chronic non-resolving inflammation.
“Chris and Nancy will add significant value to our world-class, cross-disciplinary team and scientific advisory board and will help continue the progress we have already made in developing and actualizing the significant promise of glyco-immune therapeutics for the treatment of immune-dysfunction conditions. With Dr. Adams and Ms. Thomason, we are adding a wealth of experience in business development and financing that will help move our candidate products across the finish line,” said Mohamed A. Genead, MD, Chairman & CEO of Aviceda Therapeutics.
Dr. Adams has a long history of experience in orphan drug development and biotech transactions. In 2013, he co-founded Cydan, an orphan drug accelerator focused on improving the lives of patients with rare genetic diseases, where he currently serves as Chief Executive Officer.
Ms. Thomason is the Executive Vice President and Chief Financial Officer of HAP Investment Group, LLC, a family office for the Hanns A. Pielenz family, where she is active in sourcing and managing diverse operating entities, including health care; investments in all stages of venture capital; and investments in real estate in a variety of product types.